Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline pharmaceutical sdn. bhd. - amoxycillin trihydrate; potassium clavulanate -

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin - unii:804826j2hu), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin 1000 mg - augmentin xr extended release tablets are indicated for the treatment of patients with community-acquired pneumonia or acute bacterial sinusitis due to confirmed, or suspected β-lactamase−producing pathogens (i.e., h. influenzae , m. catarrhalis , h. parainfluenzae , k. pneumoniae , or methicillin-susceptible s. aureus ) and s. pneumoniae with reduced susceptibility to penicillin (i.e., penicillin mics = 2 mcg/ml). augmentin xr is not indicated for the treatment of infections due to s. pneumoniae with penicillin mics ≥ 4 mcg/ml. data are limited with regard to infections due to s. pneumoniae with penicillin mics ≥ 4 mcg/ml (see clinical studies). of the common epidemiological risk factors for patients with resistant pneumococcal infections, only age > 65 years was studied. patients with other common risk factors for resistant pneumococcal infections (e.g., alcoholism, immune-suppressive illness, and presence of multiple co-morbid conditions) were not studied. in patients with community-acquire

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories inc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 250 mg - to reduce the development of drug‑resistant bacteria and maintain the effectiveness of augmentin (amoxicillin/clavulanate potassium) and other antibacterial drugs, augmentin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. augmentin® is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*: caused by beta‑lactamase–producing isolates of haemophilus influenzae and moraxella catarrhalis . caused by beta‑lactamase–producing isolates of h. influenzae and m. catarrhalis . caused by beta‑lactamase–producing isolates of h. influenzae and m. catarr

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin 250 mg - augmentin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: − caused by β-lactamase−producing strains of h. influenzae and m. catarrhalis . − caused by β-lactamase−producing strains of h. influenzae and m. catarrhalis . − caused by β-lactamase−producing strains of h. influenzae and m. catarrhalis . − caused by β-lactamase−producing strains of s. aureus , e. coli , and klebsiella spp. − caused by β-lactamase−producing strains of e. coli , klebsiella  spp., and enterobacter spp. while augmentin is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with augmentin due to its amoxicillin content; therefore, mixed infections caused by ampicillin-susceptible organisms and β-lactamase−producing organisms susceptible to augmentin should not require the addition of another antibiotic. because amoxicillin has greater in vitro activity again

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - clavulanic acid, quantity: 11.4 mg/ml; amoxicillin, quantity: 80 mg/ml - oral liquid, powder for - excipient ingredients: silicon dioxide; succinic acid; colloidal anhydrous silica; aspartame; xanthan gum; hypromellose; flavour - augmentin duo 400 oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology). skin and skin structure infections: urinary tract infections (complicated and uncomplicated): upper respiratory tract infections including sinusitis, otitis media: lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin. however, when there is good reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptible studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase produci

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxycillin; clavulanic acid -

Ireland - English - HPRA (Health Products Regulatory Authority)

ltt pharma limited - amoxicillin trihydrate clavulanate potassium - tablets - 250/125 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

ips healthcare limited - amoxicillin trihydrate clavulanate potassium - tablets - 500/125 milligram

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

glaxosmithkline pharmaceutical kenya limited, kenya - amoxicillin , clavulanic acid - tablets - 875mg/125mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

glaxosmithkline pharmaceutical kenya limited, kenya - amoxicillin , clavulanate - tablets - amoxicillin trihydrate 500 and clavulanate potassium, 125